According to filings with the U.S. Securities and Exchange Commission, Poseida Therapeutics is raising $24,999,999.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Eric Ostertag played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Poseida Therapeutics
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company’s pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Poseidas approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral Super piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients.

To learn more about Poseida Therapeutics, visit http://poseida.com/

Contact:
Eric Ostertag, Chief Executive Officer
858-779-3100
https://www.linkedin.com/in/ericostertag/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.